News About: Pharm. Industry
Government drug pricing policy threatening pharmaceutical industry
The recent decision by the Health Insurance Review and Assessment Service (HIRA) to evaluate the cost-effectiveness of cholesterol-lowering medicines based on individual products instead of active ingredients is putti...
Janssen starts selling Yondelis in KoreaJanssen Korea says it will start selling Yondelis (trabectedin), a treatment for soft-tissue sarcoma, from November 25. Yondelis will be the first new therapy to be commercializ...
|
61th API CHINA & INTERPHEX
The 61th API CHINA, a leading exhibition for China’s entire pharmaceutical manufacturing sector, enjoyed a robust turnout over the three-day show in Suzhou from 5–7 November 2008.
With China’s tradition based cong...
SCL signs MOU with Adicon Clinical LaboratoriesKorea’s leading reference laboratory Seoul Medical Science Institute (SCL) and China-based Adicon Clinical Laboratories, Inc. signed an agreement for the establishment of a mass...
|
Price of Lipitor to be reduced by 25%
The Ministry of Health, Welfare and Family Affairs says health insurance price of Lipitor 10 mg (atorvastatin) will be reduced from 1,290 won to 930 won.
For the assessment and cutbacks of the drug price the minist...
Estech signs drug export deal
Local active pharmaceutical ingredient (API) maker Estech Pharma signed a contract with India's largest pharmaceutical company on November 10 to export Planlukast, an antiarthmatic medicine.
The deal with Ranbaxy ...
KPMA to root out illegal rebate provision
Members of the Korea Pharmaceutical Manufacturers Association have rolled up their sleeves to stamp out undue rebate provision, citing some common types of unfair practices such as price fixing, illicit inducement of ...
Korean drugs gain popularity
Homegrown medicines and technologies have been popular among multinational companies, according to the Korea Drug Research Association.
A number of leading officials from 50 drug giants were participated in the Kor...
Choong-wae completes Phase 2 trial of avanafil
Choong-wae Pharm says its has recently completed Phase 2 study of avanafil, Japan Tanabe’s phosphodiesterase type 5, or PDE5, inhibitor product candidate for the treatment of erectile dysfunction.
The trial took ni...
Pacific targets W20 billion in Meditoxin sales
Boosted by active demand of Meditoxin (Botulinum toxin) in domestic market, Pacific Pharm has set an ambitious goal of 20 trillion in its sales next year.
The company said that the goal represents a high increase ...
